News

Observation vs MRI Screening and Pre-emptive Treatment for Spinal Cord Compression in Patients With Prostate Cancer and Spinal Metastases

04/27/2022

John Otrompke , BA, JD;

Routine MRI screening and pre-emptive treatment for malignant clinical spinal cord compression is not warranted in patients with asymptomatic castration-resistant prostate cancer and spinal metastases, according to results from the phase 3...

Routine MRI screening and...

04/27/2022

Oncology

News

Darolutamide Prolongs OS in Metastatic, Hormone-Sensitive Prostate Cancer: Results From the ARASENS Trial

04/14/2022

John Otrompke , BA, JD;

Study findings suggest darolutamide added to ADT and docetaxel significantly reduces risk of death among patients with metastatic, hormone-sensitive prostate cancer compared to treatment with ADT and docetaxel alone.

Study findings suggest...

04/14/2022

Oncology

News

Immune Checkpoint Inhibitors vs Chemotherapy for Metastatic, Castration-Resistant Prostate Cancer

04/14/2022

John Otrompke , BA, JD;

Among patients with metastatic, castration-resistant prostate cancer and high tumor mutational burden, treatment with immune checkpoint inhibitors is associated with improved outcomes compared to treatment with taxanes.

Among patients with metastatic,...

04/14/2022

Oncology

News

FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan and Companion Diagnostic Agent for Metastatic, Castration-Resistant Prostate Cancer

04/14/2022

John Otrompke , BA, JD;

The FDA approved lutetium Lu 177 vipivotide tetraxetan and a companion diagnostic agent for PSMA–positive, metastatic, castration-resistant prostate cancer previously treated with an androgen receptor inhibitor and taxane-based chemotherapy.

The FDA approved lutetium Lu 177...

04/14/2022

Oncology

Conference Coverage

Next Steps in PARP Inhibitor Targeted Approaches for Prostate Cancer: Single Agents and Combinations

03/30/2022

Janelle Bradley ;

In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Maha Hussain, MD, FACP, FASCO, discussed PARP inhibitor targeted approaches for metastatic castration-resistant prostate cancer.

In a presentation at the 2022...

03/30/2022

Oncology

Conference Coverage

Evolving Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer

03/30/2022

Janelle Bradley ;

In a presentation at the 2022 Great Debates and Updates in Genitourinary Oncology meeting, Oliver Sartor, MD, discussed the evolving treatment landscape for metastatic hormone-sensitive prostate cancer.

In a presentation at the 2022...

03/30/2022

Oncology

News

Optimal Period of ADT May Vary Depending on Receipt of Brachytherapy in High-Risk Prostate Cancer

03/30/2022

John Otrompke , BA, JD;

The optimal minimum duration of ADT may be less than 18 months for high-risk prostate cancer patients receiving external beam radiation therapy (EBRT) plus brachytherapy, but more than 18 months for patients receiving EBRT alone.

The optimal minimum duration of...

03/30/2022

Oncology

News

First-Line Abiraterone Associated With Differential Outcomes by Race in mCR Prostate Cancer

02/24/2022

First-line abiraterone is found associated with improved overall survival among African American men compared with non-Hispanic White men with metastatic castration-resistant prostate cancer.

First-line abiraterone is found...

02/24/2022

Oncology

News

FDA Approves AI-Based Software for Screening Assistance in Prostate Cancer

09/24/2021

The FDA has approved marketing of an AI software that will assist in the detection of cancer, as an adjunct to the review of digitally scanned slide images from prostate biopsies.

The FDA has approved marketing...

09/24/2021

Oncology

News

Safety, Efficacy of PSMA-Targeting Agent Being Assessed in mCRPC

07/26/2021

Investigators behind the phase 3 SPLASH trial are evaluating the safety and efficacy of 177Lu-PNT2002 for patients with mCRPC.

Investigators behind the phase 3...

07/26/2021

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology